The Two Faces of Merck

Unfortunately, there is a "Jekyll and Hyde" aspect to many pharma companies today as they struggle with the dictates of shareholders and the whole blockbuster model.  Nowhere was that more evident today than in two articles received within hours of each other. First, from Forbes, a piece on "How Merck Healed Itself" and got it's mojo back. Click here to read. Mojo wasn't evident, however, in news (far from its labs) of the  $400-million settlement of  a qui tam suit brought forth by sales manager Dean Steinke. More from the release that his legal team issued today.... Merck & Co., Inc. ("Merck"), has agreed to pay more than $400 million to the U.S., 49 states and the District of Columbia to settle qui tam whistleblower-led allegations that the pharmaceutical giant illegally defrauded Medicaid and other public healthcare programs across the U.S., according to a federal Settlement Agreement unsealed today. Merck employed four schemes to grab or maintain market share for drugs including Vioxx(R), Zocor(R), Cozaar(R), Fosamax(R), Maxalt(R), and Singulair(R), according to qui tam whistleblower lawyers Steven H. Cohen, Mark Kleiman and BethAnne Yeager, who represent the whistleblower, a former Merck district sales manager. Capping a marathon, seven-plus-year investigation among federal and state authorities and the qui tam whistleblower's legal team, the Merck case presents several major legal milestones, according to Cohen, Kleiman and Yeager, including: -- The first Government recovery from investigation into marketing of Zocor and Vioxx; -- The first fully-coordinated whistleblower-federal-state Medicaid fraud investigation; -- The first Medicaid fraud enforcement in which the States, led by Nevada, tested an innovative -- and successful -- prosecution theory; -- The first federal and state nominal price Medicaid fraud settlement; and -- The second largest civil False Claims Act ("FCA") recovery to federal and state Medicaid programs. Although Merck did not admit to wrongdoing, in addition to returning  $400 million to taxpayers, the Whitehouse Station, New Jersey-based drug manufacturer has agreed to be bound by a Corporate Integrity Agreement, according to Cohen, who, along with Yeager is associated with the Whistleblower Action Network in Chicago. "Our relator, a former Merck sales manager, blew the whistle on Merck which resulted in a nationwide investigation by federal and state prosecutors that returned hundreds of millions of taxpayer dollars to the Medicaid program," Cohen said. "When we realized the extent of the fraud, we took the evidence straight to the Government. Taking on Merck required close coordination and cooperation between us and the state and federal prosecutors. This taskforce approach and unrelenting commitment won a huge victory for the taxpayers." Kleiman said. "This landmark case exposed abuses of Medicaid's Best Price nominal price exception, and strengthened the Medicaid Rebate program to reduce the states' drug costs," Yeager said. Aside from the huge settlement, the second largest FCA civil fraud Medicaid recovery, the case marked new ground with a collaborative investigation model that saw the relator and his lawyers work closely with state and federal Government investigators to press the case. This new investigative model, Cohen said, "will become the basis for future qui tam whistleblower investigations, especially in an age of shrinking government budgets." The FCA, initially sponsored by President Abraham Lincoln to stop military fraud during the Civil War, allows private citizens with knowledge of fraud to help the Government recover ill-gotten gains and additional civil penalties. The FCA allows the Government to collect up to three times the amount it was defrauded, in addition to civil penalties of $5,500 to $11,000 per false claim. Whistleblowers whose cases settle or are won in court usually receive rewards representing 15 to 25 percent of qui tam recoveries. The federal investigation was conducted by the U.S. Attorney's Office for the Eastern District of Pennsylvania, under the direction of Patrick L. Meehan, U.S. Attorney, Assistant U.S. Attorney Virginia Gibson, Chief of the Civil Division, and Assistant U.S. Attorney Viveca Parker. Parker led the broad investigation, including the review of more than 400 boxes of Merck documents, and fostered the coordinated work of her office, the states, the whistleblower and his attorneys. At the state level, Nevada Chief Deputy Attorney General Tim Terry, head of the state's Medicaid Fraud Control Unit, worked with the whistleblower legal team on the groundbreaking companion case brought by the State of Nevada and the whistleblower. The Nevada case is part of the of the $400 million global settlement announced today. Terry and Patrick Keenan, Deputy Attorney General for Illinois, along with representatives from Attorneys' General Offices in Delaware, Massachusetts and Illinois made up the investigation team on behalf of the States' Medicaid fraud units that brought about today's global settlement. Cohen, Kleiman and Yeager praised the work of the investigation team. "The federal and state prosecutors on this case represent the highest calling of public service, Cohen said. "If it had not been for Tim Terry, Viveca Parker and the rest of the Government team we would not be announcing today's global settlement against Merck."
Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

  • <p>A consensus on the responses should then be gathered and opportunities for improvement should be discussed.-<a href="http://www.presentationsolutions.org/2011/10/25/advice-from-dr-naveed-fazlani/">Dr. Naveed Fazlani</a> </p>

    Reply

RSS feed for comments on this page | RSS feed for all comments